Coeptis Therapeutics Holdings Net Income

The latest net income for COEP is $-19M as of June 2026. That compares with $-10M in the prior-year period — down 84.7% year over year. That is below the sector sector average of $98M. Investors often review this figure alongside Coeptis Therapeutics Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, COEP's net income moved from $-10M to $-19M — a 84.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Coeptis Therapeutics Holdings's operating scale or balance-sheet position.

Against its sector companies, COEP currently prints $-19M for net income, while the sector average sits near $98M. That is roughly 119.6% below the sector mean. Large gaps often invite a closer look at Coeptis Therapeutics Holdings's growth, margins, and balance sheet.

A net income figure of $-19M for COEP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $98M. Explore the charts below for those layers of context.

After noting COEP's net income ($-19M), review year-over-year change from $-10M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.